Clinical Trial Supplies Market to surpass USD 8.7 billion in 2030, at a CAGR of 10.2%

The Clinical Trial Supplies Market was valued at USD 4.3 billion in 2023-e and projected to grow at a CAGR of 10.2% through 2030 to reach USD 8.7 billion. The clinical trial supplies market is driven by growing R&D spending by biopharmaceutical companies. The market is experiencing significant growth with increasing R&D investments by biopharmaceutical companies. An increasing number of clinical trials conducted by these firms reflects a strong focus on advancing medical innovations. Strict regulatory requirements ensure the safety and efficacy of investigational products. The industry is witnessing a rise in outsourcing activities, allowing companies to leverage specialized services. Moreover, the market is influenced by the growing prevalence of diseases, especially orphan and rare diseases, driving the need for extensive clinical research and the associated demand for diverse clinical trial supplies.

The clinical packaging, labeling, and blinding services segment is expected to account major market share over the forecast period 2024-2030. There is a high demand for customized packaging design for investigational drugs, accompanied by compliant labeling and blinding services. This ensures the integrity and proper identification of trial supplies, adhering to regulatory standards.

Bioavailability and bioequivalence (BA/BE) studies are essential for generic drug development, and they examine how quickly and to what extent a drug is absorbed into the bloodstream. Clinical trial supplies for BA/BE studies necessitate precise formulation and production to ensure comparability with the reference product.

Clinical Research Organizations (CROs) play a vital role in outsourcing various components of clinical trials, including supply chain management, packaging, and logistics. As pharmaceutical and biopharmaceutical companies increasingly collaborate with CROs to streamline operations, the CRO segment contributes significantly to the overall market. Moreover, the trend towards outsourcing various aspects of clinical trials to CROs is gaining traction due to the advantages of expertise, cost-effectiveness, and operational efficiency.

Asia Pacific clinical trial supplies market is anticipated to grow at a faster pace during the forecast period. The increasing emphasis on strategic initiatives such as partnerships, collaborations, and expansion, along with the growing influx of investments in the life sciences sector, is driving the growth of the clinical trial supplies markets in the region.

The clinical trial supplies market is characterized by the presence of various small and big players. The major market players includes Almac Group, Biocair, Catalent, Eurofins Scientific, Nuvisan, Lonza Group, PCI Pharma Services, Piramal Pharma Solutions, PRA Health Sciences, Sharp Services, and Thermo Fisher Scientific amongst others.  

Major market players are swiftly embracing advanced technologies to enhance clinical trial supplies operations and bolster their competitive stance through strategic initiatives, including mergers, acquisitions, and the introduction of new products. For instance, In August 2022, Marken acquired Bomi Group to bolster growth in healthcare logistics. This acquisition expands the company's global presence and enhances cold chain capabilities in major European and Latin American markets.